Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efpegerglucagon + efpeglenatide
- Development stage
- Preclinical
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Efpegerglucagon + efpeglenatide (also known as LAPSGlucagon Combo) is a fixed-dose combination biologic therapy being developed by Hanmi Pharmaceutical for the treatment of obesity and metabolic disorders. The combination consists of two active ingredients: efpegerglucagon (a long-acting glucagon analog) and efpeglenatide (a long-acting GLP-1 receptor agonist), both developed using Hanmi's proprietary LAPS (Long-Acting Protein/Peptide Discovery) technology platform. The drug targets both the glucagon (GCG) receptor and the GLP-1 receptor to modulate energy balance and metabolism. In preclinical studies, the combination demonstrated therapeutic benefits in animal models of obesity, dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH)/fibrosis, and chronic kidney disease. Hanmi expects that by optimizing the composition between efpegerglucagon and efpeglenatide, this combination could become a next-generation anti-obesity medication with differentiated cardiovascular, renal, and metabolic (CVRM) benefits.
- Other names
- LAPSGlucagon Combo
02
Targets
GLP1R (GLP-1R)GCGR (Glucagon receptor)
Beyond the preview
Go deeper on efpegerglucagon + efpeglenatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efpegerglucagon + efpeglenatide.